Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):365–373. doi: 10.1097/QAI.0000000000001119

Figure 5.

Figure 5

Neutralization data for iMab and iMab-based biAbs against a panel (or panel subset) of 118 tier-2 HIV-1 Env pseudoviruses in the TZM-bl assay. The corresponding (A) IC50 (μg/ml) and (B) IC80 (μg/ml) against each virus are showed. Red lines indicate the geometric means with 95% confidence intervals. IMab, 01-iMab, and 128-LM52 were tested against the entire panel of viruses, while 128-iMab, 123-iMab, 60-iMab, and 45-46-iMab were tested against 65, 71, 75, and 75 viruses from the same virus panel, respectively. The data for iMab were obtained from the literature (26).